<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02653703</url>
  </required_header>
  <id_info>
    <org_study_id>N-20130005</org_study_id>
    <nct_id>NCT02653703</nct_id>
  </id_info>
  <brief_title>L-menthol as a Topical Counter-irritant to TRPA1-induced Neurogenic Inflammation and Pain</brief_title>
  <official_title>High-concentration L-menthol as a Counter-irritant to TRPA1-induced Neurogenic Inflammation, Thermal and Mechanical Hyperalgesia Caused by Trans-cinnamaldehyde</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aalborg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to quantitatively characterize the effects of L-menthol as a topical
      counter-irritant on cutaneous pain and hyperalgesia provoked by topical application of the
      TRPA1-agonist trans-cinnamaldehyde (CA) in healthy human volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as an experimental model in healthy humans.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spontaneous pain intensity [self-reported on a visual analog scale]</measure>
    <time_frame>0-20 minutes with a sampling frequency of 1/1 min</time_frame>
    <description>Rating of the overall pain intensity on a visual analog scale (VAS ranging from &quot;No pain&quot; = 0, to &quot;worst imaginable pain&quot; =10) once every minute</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurogenic inflammation [Measured by Laser speckle flowmetry in a 3x3 cm area]</measure>
    <time_frame>20-25 minutes post induction</time_frame>
    <description>Speckle contrast flowmetry (MoorFLPI, Moor Instruments, Devon, UK). The assessment is conducted with a 30-cm distance between the head of the laser and the application area with an exposure time of 8.3ms. Single frame images are analyzed on appertaining software (MoorFLPI Review V 4.0, Moor Instruments), upon which the arithmetic mean flux (arbitrary units) is calculated. The longitudinal analysis of the spatial dispersion of neurogenic inflammation is performed using the line histogram tool. A 7-cm line centered in the area of application was placed longitudinally along the volar forearm and the perfusion intensity is recorded every 2.5 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heat hyperalgesia</measure>
    <time_frame>25-27.5 minutes post induction</time_frame>
    <description>Heat pain threshold assessments is performed with a Medoc Pathway (Medoc Ltd, Ramat Yishay, Israel) equipped with a 3 × 3 cm advanced thermal stimulator probe where the baseline temperature was set to 32 °C. Ramp stimuli of 1 °C/s are delivered and the subjects are asked to identify the heat pain threshold upon which the temperature is returned to the baseline at a rate of 5 °C/s. The test result is calculated as the arithmetic mean of the outcome from three repeated stimuli. Heat hyperalgesia is considered to be a significant drop in heat pain threshold</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical hyperalgesia</measure>
    <time_frame>27.5-30 minutes post induction</time_frame>
    <description>To evaluate the mechanical pain threshold (MPT) an electronic von Frey transducer and an electronic coVAS connected to a SENSE-Box setup is used (both items: Somedic, Hörby, Sweden). Five ramp stimuli from 0-110 g at a rate of 5g/1 sec with the default stimulus probe is conducted at different locations within the application area. The subjects are instructed to continuously rate the perceived pain on the coVAS ranging from &quot;No pain&quot; (0) to &quot;worst imaginable pain&quot; (10). The arithmetic mean of the VAS scores yields three MPTs (fixed to VAS = 0.5, 1 and 2) and an area-under-the-curve (AUC).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Inflammation</condition>
  <condition>Pruritus</condition>
  <condition>Hyperalgesia</condition>
  <arm_group>
    <arm_group_label>Vehicle, topical ethanol 96%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Exposure: 10 % topical trans-cinnamaldehyde [CAS Number: 14371-10-9] Vehicle: 96% ethanol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical L-menthol 40%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exposure: 10 % trans-cinnamaldehyde [CAS Number: 14371-10-9] Intervention: 40% l-menthol [CAS Number: 2216-51-5] Vehicle: 96% ethanol</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Topical L-menthol 40%</intervention_name>
    <description>Naturally occurring local anaesthetic, counterirritant and TPRM8-agonist. CAS Number: 2216-51-5</description>
    <arm_group_label>Topical L-menthol 40%</arm_group_label>
    <other_name>Menthol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle, topical ethanol 96%</intervention_name>
    <description>Organic solvent CAS Number: 64-17-5</description>
    <arm_group_label>Vehicle, topical ethanol 96%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 healthy men and women aged 18-50 years willing to abstain from alcohol, nicotine,
             caffeine and pain medication 24 hours before experimental sessions

        Exclusion Criteria:

          -  Pregnancy

          -  Skin disorders (e.g. contact eczema)

          -  Chronic pain conditions

          -  Drug addiction defined as the use of cannabis, opioids or other drugs

          -  Previous neurologic, musculoskeletal or mental illnesses

          -  Lack of ability to cooperate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Over-the-CounterOTCDrugs/StatusofOTCRulemakings/UCM077928.pdf</url>
    <description>FDA-statement on topical anti-irritants</description>
  </link>
  <reference>
    <citation>Olsen RV, Andersen HH, Møller HG, Eskelund PW, Arendt-Nielsen L. Somatosensory and vasomotor manifestations of individual and combined stimulation of TRPM8 and TRPA1 using topical L-menthol and trans-cinnamaldehyde in healthy volunteers. Eur J Pain. 2014 Oct;18(9):1333-42. doi: 10.1002/j.1532-2149.2014.494.x. Epub 2014 Mar 25.</citation>
    <PMID>24664788</PMID>
  </reference>
  <reference>
    <citation>Højland CR, Andersen HH, Poulsen JN, Arendt-Nielsen L, Gazerani P. A human surrogate model of itch utilizing the TRPA1 agonist trans-cinnamaldehyde. Acta Derm Venereol. 2015 Sep;95(7):798-803. doi: 10.2340/00015555-2103.</citation>
    <PMID>25792226</PMID>
  </reference>
  <reference>
    <citation>Namer B, Seifert F, Handwerker HO, Maihöfner C. TRPA1 and TRPM8 activation in humans: effects of cinnamaldehyde and menthol. Neuroreport. 2005 Jun 21;16(9):955-9.</citation>
    <PMID>15931068</PMID>
  </reference>
  <reference>
    <citation>Namer B, Kleggetveit IP, Handwerker H, Schmelz M, Jorum E. Role of TRPM8 and TRPA1 for cold allodynia in patients with cold injury. Pain. 2008 Sep 30;139(1):63-72. doi: 10.1016/j.pain.2008.03.007. Epub 2008 Apr 25.</citation>
    <PMID>18440147</PMID>
  </reference>
  <reference>
    <citation>Andersen HH, Olsen RV, Møller HG, Eskelund PW, Gazerani P, Arendt-Nielsen L. A review of topical high-concentration L-menthol as a translational model of cold allodynia and hyperalgesia. Eur J Pain. 2014 Mar;18(3):315-25. doi: 10.1002/j.1532-2149.2013.00380.x. Epub 2013 Aug 20. Review.</citation>
    <PMID>23963768</PMID>
  </reference>
  <reference>
    <citation>Leslie TA, Greaves MW, Yosipovitch G. Current topical and systemic therapies for itch. Handb Exp Pharmacol. 2015;226:337-56. doi: 10.1007/978-3-662-44605-8_18. Review.</citation>
    <PMID>25861788</PMID>
  </reference>
  <reference>
    <citation>Heyneman CA. Topical nonsteroidal antiinflammatory drugs for acute soft tissue injuries. Ann Pharmacother. 1995 Jul-Aug;29(7-8):780-2. Review.</citation>
    <PMID>8520097</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2016</study_first_posted>
  <last_update_submitted>January 11, 2016</last_update_submitted>
  <last_update_submitted_qc>January 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University</investigator_affiliation>
    <investigator_full_name>Parisa Gazerani</investigator_full_name>
    <investigator_title>Professor, PharmD, Ph.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Pruritus</mesh_term>
    <mesh_term>Hyperalgesia</mesh_term>
    <mesh_term>Neurogenic Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Menthol</mesh_term>
    <mesh_term>Cinnamic aldehyde</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

